Viz.ai
Verified Oct 16, 2026 ActiveCare-coordination platform that reads hospital imaging for strokes, clots and bleeds and pages the right team
Listed on EffectHub ·
Pricing
- Pricing model
- Contact sales
No public price: the site offers 'Request a demo' and 'Speak to an expert'. Hospital contracts are negotiated per institution and module; in the United States some stroke-triage use has been reimbursed under a CMS New Technology Add-on Payment, which is a matter for the buyer's billing team rather than a list price.
Use tool ↗About Viz.ai
Viz.ai runs FDA-cleared algorithms over CT, MRI, ECG and other hospital data as it is acquired, flags time-critical findings such as large-vessel-occlusion stroke, intracranial haemorrhage, pulmonary embolism, aortic disease and cardiomyopathy, and sends the images and an alert to the specialist team's phones so treatment decisions start before the formal read. Suites cover neuro, vascular, cardio, pulmonary, radiology, trauma and oncology, with pilots in osteoporosis and respiratory disease, all on the Viz.ai One coordination platform with mobile and desktop clients. The company says it ships more than 50 FDA-cleared algorithms, sells to hospitals through demos and contracts, and runs a life-sciences arm with pharmaceutical and device partners. Viz.ai, Inc. was founded in 2016 by neurosurgeon Chris Mansi and machine-learning researcher David Golan.
- API
- Not confirmed
- Last verified
- Oct 16, 2026
Verified sources
- Home page: Viz.ai One care coordination platform; Neuro, Vascular, Cardio, Pulmonary, Radiology, Trauma and Oncology suites; Viz Assist; pilot programmes; Life Sciences; 'more than 50 FDA-cleared AI algorithms'; mobile and desktop clients; 'Request a demo' with no pricing; footer © Viz.ai, Inc. (15 October 2026)viz.ai ↗
- About page: founded in 2016 by Dr Chris Mansi, a neurosurgeon, and Dr David Golan, a machine-learning post-doc; legal entity Viz.ai, Inc. (15 October 2026)viz.ai ↗
Is Viz.ai legit?
We don’t label tools safe or unsafe. Below are the records we checked ourselves, each with the date we read it.
- Domain registered
- Dec 16, 2017 (8 years ago)Registry record (RDAP), registrar 101domain GRS Limited, looked up Sep 6, 2026
- TLS certificate
- Issued by Google Trust Services, valid until Dec 30, 2026Seen in our own connection to the site on Oct 16, 2026
- Last checked
- Oct 16, 2026The site answered
- On the market since
- 2016The vendor's own material, read by us
- Operated by
- Viz.ai, Inc., United StatesOur research, card verified Oct 15, 2026
Pros & cons of Viz.ai
Viz.ai is clinical infrastructure rather than a tool anyone signs up for: it sits on a hospital's imaging feed, and its value is the minutes it shaves between a scan and a specialist seeing it. The stroke work is the proven core, with the longest track record and the most clearances; the newer cardio, oncology and pilot suites are expansions a buyer should evaluate module by module. Nothing is priced publicly, procurement is an enterprise sale with IT and compliance review, and the algorithms are only as useful as the care pathway the hospital builds around the alerts.
Pros
- More than 50 FDA-cleared algorithms across neuro, vascular, cardio, pulmonary, trauma and oncology
- Alerts and images go to the specialist's phone, so the care pathway starts before the radiology read
- One platform (Viz.ai One) rather than a separate vendor per finding
- Founded in 2016 with a named clinical founder, so the stroke pathway has years of deployment behind it
Cons
- No public pricing, trial or self-serve path; every engagement is a sales process
- Value depends on hospital workflow changes around the alerts, not on the software alone
- Newer suites and pilot programmes have less published evidence than the stroke module
- Headquarters and funding details are not stated on the site
Best for
- Hospital systems and stroke networks that want imaging-triggered alerts to reach neurointerventional teams faster
- Health systems consolidating several triage algorithms (stroke, PE, aortic, cardiac) under one coordination platform
- Pharma and device companies looking for a deployed channel to identify patients for specific therapies
Not for
- Individual clinicians or small clinics, since it is sold to institutions through demos and contracts
- Anyone expecting a self-serve or priced product; there is no public pricing or trial
Watch out: Each module is cleared and sold separately: a quote for stroke triage does not include PE, aortic or cardiac detection, and each addition is a new integration and contract.
Alternatives to Viz.ai
Viz.ai head-to-head
Side-by-side fact sheets against the competitors our research or their makers name — pricing, platforms, API and both verdicts on one page.
AI tools by profession
Healthcare & Medical is one of the jobs on this page: